Skin Cancer: Safety and Efficacy of Pembrolizumab (trade name Keytruda) Compared to
What is the safety and effectiveness of pembrolizumab compared to placebo in participants
with surgically removed stage II melanoma?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
Pembrolizumab is an antibody that blocks a protective mechanism of cancer cells and
thereby allows the immune system to destroy them. This study will evaluate pembrolizumab
compared to placebo in participants after the surgical removal of stage II melanoma.
Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind
design for up to 17 cycles. Part 2 is an open-label design for participants who receive
placebo in Part 1 or who stop treatment after receiving 17 cycles of pembrolizumab
in Part 1. They may be eligible to receive up to 35 additional cycles of pembrolizumab
in Part 2.
Study Reference #: IMEL18060
Lead Researcher (Principal Investigator)
Deepak Sahasrabudhe, MD
Study Contact InformationStudy Coordinator: Park Bogan
Phone: (585) 276-4415
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search